Venlafaxine for the control of hot flashes: results of a longitudinal continuation study.

Debra Barton, Vasseur Beth La, Charles Lawrence Loprinzi, Paul Novotny, Mary Beth Wilwerding, Jeff A Sloan

Research output: Contribution to journalArticle

72 Citations (Scopus)

Abstract

PURPOSE/OBJECTIVES: To evaluate the intermediate term efficacy and toxicity of the use of venlafaxine for the control of hot flashes. DESIGN: An open-label continuation phase study following a double-blind, randomized, placebo-controlled clinical trial that tested three doses of venlafaxine for the control of hot flashes. SETTING: North Central Cancer Treatment Group institutions. SAMPLE: 102 postmenopausal women. METHODS: Women could titrate venlafaxine to optimum efficacy while recording daily hot flash counts and weekly toxicity information. MAIN RESEARCH VARIABLES: Hot flash frequency, hot flash score. FINDINGS: The reduction in hot flashes previously reported in the randomized study phase was maintained during the open-label study. Toxicity did not appear to increase over time. CONCLUSIONS: The data from this study provides evidence that venlafaxine has intermediate term efficacy and good tolerability as a treatment for hot flashes. IMPLICATIONS FOR NURSING PRACTICE: Nurses can inform symptomatic women that an effective nonhormonal alternative exists to control their hot flashes.

Original languageEnglish (US)
Pages (from-to)33-40
Number of pages8
JournalOncology Nursing Forum
Volume29
Issue number1
StatePublished - Jan 2002

Fingerprint

Hot Flashes
Longitudinal Studies
Venlafaxine Hydrochloride
Nursing
Randomized Controlled Trials
Nurses
Placebos

ASJC Scopus subject areas

  • Oncology(nursing)

Cite this

Venlafaxine for the control of hot flashes : results of a longitudinal continuation study. / Barton, Debra; La, Vasseur Beth; Loprinzi, Charles Lawrence; Novotny, Paul; Wilwerding, Mary Beth; Sloan, Jeff A.

In: Oncology Nursing Forum, Vol. 29, No. 1, 01.2002, p. 33-40.

Research output: Contribution to journalArticle

Barton, Debra ; La, Vasseur Beth ; Loprinzi, Charles Lawrence ; Novotny, Paul ; Wilwerding, Mary Beth ; Sloan, Jeff A. / Venlafaxine for the control of hot flashes : results of a longitudinal continuation study. In: Oncology Nursing Forum. 2002 ; Vol. 29, No. 1. pp. 33-40.
@article{1742c10a46534edba62bf2fa0544f3ec,
title = "Venlafaxine for the control of hot flashes: results of a longitudinal continuation study.",
abstract = "PURPOSE/OBJECTIVES: To evaluate the intermediate term efficacy and toxicity of the use of venlafaxine for the control of hot flashes. DESIGN: An open-label continuation phase study following a double-blind, randomized, placebo-controlled clinical trial that tested three doses of venlafaxine for the control of hot flashes. SETTING: North Central Cancer Treatment Group institutions. SAMPLE: 102 postmenopausal women. METHODS: Women could titrate venlafaxine to optimum efficacy while recording daily hot flash counts and weekly toxicity information. MAIN RESEARCH VARIABLES: Hot flash frequency, hot flash score. FINDINGS: The reduction in hot flashes previously reported in the randomized study phase was maintained during the open-label study. Toxicity did not appear to increase over time. CONCLUSIONS: The data from this study provides evidence that venlafaxine has intermediate term efficacy and good tolerability as a treatment for hot flashes. IMPLICATIONS FOR NURSING PRACTICE: Nurses can inform symptomatic women that an effective nonhormonal alternative exists to control their hot flashes.",
author = "Debra Barton and La, {Vasseur Beth} and Loprinzi, {Charles Lawrence} and Paul Novotny and Wilwerding, {Mary Beth} and Sloan, {Jeff A}",
year = "2002",
month = "1",
language = "English (US)",
volume = "29",
pages = "33--40",
journal = "Oncology Nursing Forum",
issn = "0190-535X",
publisher = "Oncology Nursing Society",
number = "1",

}

TY - JOUR

T1 - Venlafaxine for the control of hot flashes

T2 - results of a longitudinal continuation study.

AU - Barton, Debra

AU - La, Vasseur Beth

AU - Loprinzi, Charles Lawrence

AU - Novotny, Paul

AU - Wilwerding, Mary Beth

AU - Sloan, Jeff A

PY - 2002/1

Y1 - 2002/1

N2 - PURPOSE/OBJECTIVES: To evaluate the intermediate term efficacy and toxicity of the use of venlafaxine for the control of hot flashes. DESIGN: An open-label continuation phase study following a double-blind, randomized, placebo-controlled clinical trial that tested three doses of venlafaxine for the control of hot flashes. SETTING: North Central Cancer Treatment Group institutions. SAMPLE: 102 postmenopausal women. METHODS: Women could titrate venlafaxine to optimum efficacy while recording daily hot flash counts and weekly toxicity information. MAIN RESEARCH VARIABLES: Hot flash frequency, hot flash score. FINDINGS: The reduction in hot flashes previously reported in the randomized study phase was maintained during the open-label study. Toxicity did not appear to increase over time. CONCLUSIONS: The data from this study provides evidence that venlafaxine has intermediate term efficacy and good tolerability as a treatment for hot flashes. IMPLICATIONS FOR NURSING PRACTICE: Nurses can inform symptomatic women that an effective nonhormonal alternative exists to control their hot flashes.

AB - PURPOSE/OBJECTIVES: To evaluate the intermediate term efficacy and toxicity of the use of venlafaxine for the control of hot flashes. DESIGN: An open-label continuation phase study following a double-blind, randomized, placebo-controlled clinical trial that tested three doses of venlafaxine for the control of hot flashes. SETTING: North Central Cancer Treatment Group institutions. SAMPLE: 102 postmenopausal women. METHODS: Women could titrate venlafaxine to optimum efficacy while recording daily hot flash counts and weekly toxicity information. MAIN RESEARCH VARIABLES: Hot flash frequency, hot flash score. FINDINGS: The reduction in hot flashes previously reported in the randomized study phase was maintained during the open-label study. Toxicity did not appear to increase over time. CONCLUSIONS: The data from this study provides evidence that venlafaxine has intermediate term efficacy and good tolerability as a treatment for hot flashes. IMPLICATIONS FOR NURSING PRACTICE: Nurses can inform symptomatic women that an effective nonhormonal alternative exists to control their hot flashes.

UR - http://www.scopus.com/inward/record.url?scp=0036365314&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0036365314&partnerID=8YFLogxK

M3 - Article

C2 - 11817491

AN - SCOPUS:0036365314

VL - 29

SP - 33

EP - 40

JO - Oncology Nursing Forum

JF - Oncology Nursing Forum

SN - 0190-535X

IS - 1

ER -